Mounjaro Kwikpen (Tirzepatide)

Tirzepatide activates both GIP and GLP‑1 receptors, which together increase insulin secretion, reduce glucagon release, slow gastric emptying and enhance satiety, resulting in lower post‑prandial glucose levels and modest weight loss.

The dose of tirzepatide is individualized by the prescribing healthcare professional. The prescriber determines the starting dose, titration schedule and maintenance dose based on the patient’s clinical response and tolerability.

Safety of tirzepatide in pregnancy and lactation has not been established. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision must be made by a qualified clinician.

To place an order, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and any necessary import documentation.

Tirzepatide is a dual GIP/GLP‑1 receptor agonist, offering both the glucose‑lowering effects of GLP‑1 agents and additional metabolic benefits from GIP activation. Clinical studies suggest greater reductions in HbA1c and body weight compared with many single‑target GLP‑1 analogues, though individual response varies.

Mounjaro Kwikpen must be stored refrigerated at 2‑8 °C, protected from light, and must not be frozen or shaken. If a pen is taken out of refrigeration, it may be used for up to 14 days at controlled room temperature (≤ 30 °C) before discarding.

The medication is delivered via a prefilled autoinjector pen for subcutaneous injection. Patients or caregivers inject the prescribed dose into the abdomen, thigh or upper arm, rotating sites with each administration, typically once weekly.

Serious risks include pancreatitis, severe hypoglycaemia (especially when combined with insulin or sulfonylureas), gallbladder disease, acute kidney injury and, based on animal data, potential thyroid C‑cell tumours. Prompt medical attention is required if any concerning symptoms arise.

Mounjaro Kwikpen is contraindicated in individuals with a known hypersensitivity to tirzepatide or any excipients, and it should be avoided in patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2.